Indicated for: chronic myeloid leukemia
Route of administration: oral
Substance: dasatinib (tyrosine kinase inhibitor)
ATC: L01EA02 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | BCR-ABL tyrosine kinase inhibitors)
Dasatinibum is a medication used for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with Philadelphia chromosome positivity. It acts as a tyrosine kinase inhibitor, blocking signals that promote cancer cell growth.
The medication is taken orally, usually once daily, and is effective in reducing the number of leukemic cells and prolonging patient survival. It is used in both chronic and advanced phases of the disease.
Side effects may include fluid retention, nausea, diarrhea, fatigue, and muscle pain. In rare cases, severe complications such as pulmonary hypertension or bone marrow suppression may occur. Regular monitoring is essential.
Consult your doctor to discuss the benefits and risks of treatment with Dasatinibum. Follow the prescribed dosage and adhere to all medical recommendations.